Navigation Links
Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
Date:5/7/2009

y in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this press release to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
3. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
4. Savient Announces Appointment of David Gionco as Chief Financial Officer
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
7. Savient Submits Biologics License Application (BLA) for pegloticase
8. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
9. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
10. Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
11. GeoVax Labs, Inc. Announces First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... CA (PRWEB) November 21, 2014 Why ... that makes Albert Einstein so instantly recognizable? Why have ... physicist, mathematician, astronomer and author Hilton Ratcliffe seeks out ... have nothing at all to do with science. In ... Harbor Publishing , November 21, 2014), Ratcliffe puts it ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014 /PRNewswire/ ... patient has been dosed in its Phase 1 ... and cisplatin for the treatment of malignant pleural ...  Polaris Group is conducting clinical trials on ADI-PEG ... other agents, for the treatment of several other ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... ended September 30, 2014.  Biorem,s complete 2014 third quarter financial statements ... Financial Summary:Three-months ended September 30, , Nine-months ended ... , 2014 , 2013 , ... 5,281 , 6,715 , 14,476 Gross ...
(Date:11/18/2014)... LA (PRWEB) November 17, 2014 ... build-to-order, open architecture blade-based and rackmount computing infrastructure, ... Tesla® K80 dual-GPU accelerator throughout its GPU-enabled blade ... pair of the company’s latest proprietary 80-lane Gen3 ... eight discrete NVIDIA Tesla K80 dual-GPU accelerator cards ...
Breaking Biology Technology:“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 2“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 3“Stephen Hawking Smoked My Socks” Sparks Controversy in Science World 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Biorem Reports Third Quarter Results 2Biorem Reports Third Quarter Results 3Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 2Cirrascale® Expands Multi-GPU Peering Solutions with Support for New NVIDIA Tesla K80 Dual-GPU Accelerators 3
... for In-Vitro / In-Vivo ... Correlation Modeling in Drug Development, MOUNTAIN VIEW, ... a leading provider of software, strategic,consulting, and regulatory services ... MS, Director of,Training and Pre-Sales, will speak to members ...
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on ... request a hearing before The NASDAQ Listing,Qualifications Panel ... delist the Company,s common stock from The NASDAQ ... The NASDAQ Stock Market ("NASDAQ") on,June 17, 2008 ...
... 2008 / b3c newswire /  - Rentschler ... biopharmazeutischer Arzneimittel gibt die Inbetriebnahme einer 2.500 ... nun über neun unabhängige GMP-Produktionslinien mit Arbeitsvolumen ... für die Herstellung von klinischen Prüfmustern und ...
Cached Biology Technology:Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 2Pharsight to Present on IVIVC at Bioequivalence & Bioavailability Strategies Conference 3Insmed to Request Hearing Before NASDAQ Panel to Review NASDAQ Staff Determination 2Rentschler Biotechnologie erweitert Kapazitten fr Produktion in Sugetierzellen 2
(Date:11/6/2014)... metastasis, yet progress in preventing and treating migratory ... particularly challenging to design drugs that work against ... biology at Harvard Medical School. , "Unfortunately, ... metastasized." , Gujral and colleagues have now identified ... understand how metastasis begins. Their findings may also ...
(Date:11/5/2014)... associate professor of biology in the UTSA College ... the nation selected to receive a two-year $300,00 ... Exploratory Research (EAGER). The funding supports President Obama,s ... to create new technology that will demystify complex ... behaviors in neuroscience are broken into the interactions ...
(Date:11/4/2014)... LAKE CITY, Nov. 5, 2014 – University of Utah ... enzymes to help jet fuel produce electricity without needing ... be used to power portable electronics, off-grid power and ... online today in the American Chemical Society journal ... electricity through a chemical reaction between a fuel and ...
Breaking Biology News(10 mins):Migration negation 2Migration negation 3UTSA biology professor awarded $300,000 NSF grant for brain research 2UTSA biology professor awarded $300,000 NSF grant for brain research 3Jet-fueled electricity at room temperature 2
... 30,000 genes (the number is hotly contested), but they use ... the protein molecules that domost of the work in the ... Greek prota, meaning "of primary importance." Proteins are created ... fold spontaneously into what is called their "native form" in ...
... a new forum for the best pre-clinicaland translational science ... 22-23, 2011, immediately preceding the European Congress on Osteoporosis ... chaired by Gerard Karsenty, Professor and Chair, Genetics & ... leading scientists from the bone biology arena. All programme ...
... patients and state-of-the-art biochemical techniques, a Florida State ... of "biomarkers" that might provide earlier warnings of ... "Biomarkers are indicators of certain biological and pathological ... Qing-Xiang "Amy" Sang, a professor in Florida State,s ...
Cached Biology News:New method takes snapshots of proteins as they fold 2New method takes snapshots of proteins as they fold 3New method takes snapshots of proteins as they fold 4New method takes snapshots of proteins as they fold 5An earlier start on diagnosing breast, prostate cancers 2An earlier start on diagnosing breast, prostate cancers 3An earlier start on diagnosing breast, prostate cancers 4
... Analog (ARCA) is a modified cap analog ... to m7G) is replaced with OCH3. Because ... only initiate transcription with the remaining hydroxyl ... forward orientation. As a result, unlike transcripts ...
iEMS Thermal Microplate Holder...
... A modified nucleotide structure called a ... of most naturally-occurring eukaryotic mRNAs and ... Analog for a portion of the ... transcription reaction results in the synthesis ...
... PTOs are internucleotide modifications, where one ... replaced by a sulphur atom. This modification ... are available as Full-PTOs ... with thio-caps Several internucleotide ...
Biology Products: